SemBioSys' plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclini... (n performed at four outside laboratories...)

SemBioSys' plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models

Date:5/19/2009

n performed at four outside laboratories and each one has shown the molecule to be biologically active.

Dr. Shah noted, "These results are promising and demonstrate that plant-derived Apo AI(Milano) functions in a manner consistent with its known effects in test animals. The use of plants as an inexpensive, abundant source of Apo AI(Milano) opens up many possibilities for the therapeutic use of Apo AI(Milano) and we are very enthusiastic to continue our research with this new source of the molecule."

Dr Maurice Moloney, Chief Scientific Officer at SemBioSys, commented, "Dr. Shah's work, along with studies conducted by additional academic and commercial parties, has helped demonstrate the viability of our plant-made Apo AI(Milano) as a therapeutic candidate. Given the very high prevalence and human toll of atherosclerosis, such as heart attack and stroke, we are very encouraged by this progress."

About SemBioSys' Apo AI(Milano)

Apo AI (also known as apolipoprotein AI) is a naturally occurring human protein being developed as a cardiovascular therapy to stabilize and reverse atherosclerotic plaque deposition for the prevention and treatment of cardiovascular disease. Apo AI is believed by many clinicians to be the archetype for a new generation of cardiovascular drugs (HDL therapies). Apo AI is the major apolipoprotein associated with HDL, commonly referred to as "good cholesterol", which naturally removes plaque from arteries. Published studies have shown that Apo AI(Milano), which is a variant of Apo AI in a phospholipid formulation, could reduce plaque volume at a level and speed unattainable with any current drug therapy. If successfully commercialized, predicted high dosing (multiple grams per course of patient treatment) coupled with a large patient population would be expected to drive volume demand of several tons of Apo AI(Milano) per year, underscoring the value of a highly scalable, plant manufacturing solut
'/>"/>

2

GOOD

Page: 1 2 3 4
Related biology technology :

1. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
2. SemBioSys provides update on insulin program
3. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
4. SemBioSys announces senior management changes
5. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
6. SemBioSys begins phase I/II trial of insulin produced in plant seeds
7. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
8. SemBioSys announces second quarter 2008 financial and operational results
9. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
10. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
11. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference

Post Your Comments:

SemBioSys' plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclini...(n performed at four outside laboratories...)